TBPH Quote, Financials, Valuation and Earnings

Innoviva, Inc. has a net margin of 18.08% compared to Theravance Biopharma, Inc.'s net margin of 80.81%. Theravance Biopharma, Inc.'s return on equity of 14.9% beat Innoviva, Inc.'s return on equity of 17.06%.

Theravance Biopharma, Inc. has a consensus price target of $26.71, signalling upside risk potential of 36.79%. On the other hand Innoviva, Inc. has an analysts' consensus of $32.50 which suggests that it could grow by 43.17%. Given that Innoviva, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Innoviva, Inc. is more attractive than Theravance Biopharma, Inc..

Theravance Biopharma, Inc. has a beta of 0.148, which suggesting that the stock is 85.221% less volatile than S&P 500. In comparison Innoviva, Inc. has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.321%.

Theravance Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theravance Biopharma, Inc. pays -- of its earnings as a dividend. Innoviva, Inc. pays out -- of its earnings as a dividend.

Theravance Biopharma, Inc. quarterly revenues are $20M, which are smaller than Innoviva, Inc. quarterly revenues of $111.3M. Theravance Biopharma, Inc.'s net income of $3.6M is lower than Innoviva, Inc.'s net income of $89.9M. Notably, Theravance Biopharma, Inc.'s price-to-earnings ratio is 34.72x while Innoviva, Inc.'s PE ratio is 16.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma, Inc. is 12.26x versus 4.46x for Innoviva, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 18.08% compared to Theravance Biopharma, Inc.'s net margin of -19.69%. Theravance Biopharma, Inc.'s return on equity of 14.9% beat Moderna, Inc.'s return on equity of -30.18%.

Theravance Biopharma, Inc. has a consensus price target of $26.71, signalling upside risk potential of 36.79%. On the other hand Moderna, Inc. has an analysts' consensus of $39.00 which suggests that it could fall by -7.65%. Given that Theravance Biopharma, Inc. has higher upside potential than Moderna, Inc., analysts believe Theravance Biopharma, Inc. is more attractive than Moderna, Inc..

Theravance Biopharma, Inc. has a beta of 0.148, which suggesting that the stock is 85.221% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Theravance Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theravance Biopharma, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Theravance Biopharma, Inc. quarterly revenues are $20M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Theravance Biopharma, Inc.'s net income of $3.6M is higher than Moderna, Inc.'s net income of -$200M. Notably, Theravance Biopharma, Inc.'s price-to-earnings ratio is 34.72x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma, Inc. is 12.26x versus 7.33x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 18.08% compared to Theravance Biopharma, Inc.'s net margin of -301.29%. Theravance Biopharma, Inc.'s return on equity of 14.9% beat Nektar Therapeutics's return on equity of -327.67%.

Theravance Biopharma, Inc. has a consensus price target of $26.71, signalling upside risk potential of 36.79%. On the other hand Nektar Therapeutics has an analysts' consensus of $123.43 which suggests that it could grow by 73.04%. Given that Nektar Therapeutics has higher upside potential than Theravance Biopharma, Inc., analysts believe Nektar Therapeutics is more attractive than Theravance Biopharma, Inc..

Theravance Biopharma, Inc. has a beta of 0.148, which suggesting that the stock is 85.221% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.

Theravance Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Theravance Biopharma, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Theravance Biopharma, Inc. quarterly revenues are $20M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Theravance Biopharma, Inc.'s net income of $3.6M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Theravance Biopharma, Inc.'s price-to-earnings ratio is 34.72x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma, Inc. is 12.26x versus 73.55x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Oramed Pharmaceuticals, Inc. has a net margin of 18.08% compared to Theravance Biopharma, Inc.'s net margin of -382.1%. Theravance Biopharma, Inc.'s return on equity of 14.9% beat Oramed Pharmaceuticals, Inc.'s return on equity of 27.49%.

Theravance Biopharma, Inc. has a consensus price target of $26.71, signalling upside risk potential of 36.79%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could fall by --. Given that Theravance Biopharma, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Theravance Biopharma, Inc. is more attractive than Oramed Pharmaceuticals, Inc..

Theravance Biopharma, Inc. has a beta of 0.148, which suggesting that the stock is 85.221% less volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.342, suggesting its more volatile than the S&P 500 by 34.249%.

Theravance Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals, Inc. offers a yield of 7.69% to investors and pays a quarterly dividend of $0.25 per share. Theravance Biopharma, Inc. pays -- of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Theravance Biopharma, Inc. quarterly revenues are $20M, which are larger than Oramed Pharmaceuticals, Inc. quarterly revenues of --. Theravance Biopharma, Inc.'s net income of $3.6M is lower than Oramed Pharmaceuticals, Inc.'s net income of $48.4M. Notably, Theravance Biopharma, Inc.'s price-to-earnings ratio is 34.72x while Oramed Pharmaceuticals, Inc.'s PE ratio is 3.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Theravance Biopharma, Inc. is 12.26x versus 67.65x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.